Search

Displaying results 2021 - 2030 of 10000 in total
  1. Drug

    Moricizine

    go.drugbank.com/drugs/DB00680
    ApprovedWithdrawn

    An antiarrhythmia agent used primarily for ventricular rhythm disturbances.

    Synonyms: ethyl 10-(β-N-morpholinylpropionyl)phenothiazine-2-carbamate
  2. Drug

    Nitrazepam

    go.drugbank.com/drugs/DB01595
    Approved

    A benzodiazepine derivative used as an anticonvulsant and hypnotic.

    Synonyms: N-desmethylnimetazepamProducts: EATAN N
  3. Drug

    NN-8828

    go.drugbank.com/drugs/DB18361
    Investigational

    NN-8828 is an anti-interleukin 21 monoclonal antibody.

  4. Drug

    Pyridostigmine

    go.drugbank.com/drugs/DB00545
    ApprovedInvestigational

    [A231009, A231014, L32413, L32418] Pyridostigmine was granted initial FDA approval on April 6, 1955, as an oral tablet. … Myasthenia gravis is an autoimmune disease involving dysfunction at the neuromuscular junction, most commonly due to autoantibodies directed against the acetylcholine receptor (AChR), which results in

    International brands: Kalymin N
  5. Drug

    NOX-100

    go.drugbank.com/drugs/DB05799
    Investigational

    NOX-100 is the first in a series of proprietary NO neutralizing compounds Medinox is developing to bind and inactivate NO, a simple gas molecule that is a key biological messenger in the body. … NOX-100 is the new nitric oxide (NO) neutralizing agent being developed by San Diego-based Medinox -- demonstrated its effectiveness and potential as a therapeutic to treat hemorrhagic shock.

  6. Drug

    Brilliant blue G

    go.drugbank.com/drugs/DB15594
    Approved

    Brilliant Blue G is used in an ophthalmic solution for staining the internal limiting membrane (ILM) of the eye during ophthalmic procedures. … Brilliant blue G, like its name, imparts a vibrant blue color, facilitating identification of the ILM. It was approved by the FDA for ophthalmic use on December 20, 2019.[L10830]

    Categories: Compounds used in a research, industrial, or household setting
  7. Drug

    Veglin

    go.drugbank.com/drugs/DB05890
    Experimental

    VEGF-AS (Veglin) is an anti-angiogenesis non-chemotherapy drug (angiogenesis inhibitor) that was developed by VasGene Therapeutics, Inc. for the treatment of a variety of malignancies including mesothelioma

  8. Drug

    Miltefosine

    go.drugbank.com/drugs/DB09031
    ApprovedInvestigational

    Miltefosine is a broad spectrum antimicrobial, anti-leishmanial, phospholipid drug that was originally developed in the 1980s as an anti-cancer agent. … It is currently the only recognized oral agent used to treat visceral, cutaneous, and mucosal forms of leishmaniasis, a neglected tropical disease.

  9. Drug

    Tedizolid

    go.drugbank.com/drugs/DB14569
    ApprovedInvestigational

    This product is currently available as both an oral tablet and as a powder for intravenous injection.[L11232] … Drug-resistant bacteria, such as methicillin-resistant _Staphylococcus aureus_, vancomycin-resistant _Enterococcus faecium_, and penicillin-resistant _Streptococcus penumoniae_, represent a massive public

    Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates
  10. Drug

    Tralokinumab

    go.drugbank.com/drugs/DB12169
    ApprovedInvestigational

    While AD is a heterogenous condition with a variety of apparent genetic and environmental causes,[A242422] it is primarily driven by the pro-inflammatory cytokine interleukin-13 (IL-13). … [A242427] Tralokinumab is a fully human IgG4 monoclonal antibody targeted against IL-13.